GRCE
Price
$2.96
Change
+$0.02 (+0.68%)
Updated
Jun 27, 04:12 PM (EDT)
Capitalization
41.21M
IMVT
Price
$16.10
Change
-$0.29 (-1.77%)
Updated
Jun 27, 04:59 PM (EDT)
Capitalization
2.75B
39 days until earnings call
Interact to see
Advertisement

GRCE vs IMVT

Header iconGRCE vs IMVT Comparison
Open Charts GRCE vs IMVTBanner chart's image
Grace Therapeutics
Price$2.96
Change+$0.02 (+0.68%)
Volume$642
Capitalization41.21M
Immunovant
Price$16.10
Change-$0.29 (-1.77%)
Volume$66.55K
Capitalization2.75B
GRCE vs IMVT Comparison Chart in %
Loading...
GRCE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IMVT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GRCE vs. IMVT commentary
Jun 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GRCE is a Hold and IMVT is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 28, 2025
Stock price -- (GRCE: $2.98 vs. IMVT: $16.10)
Brand notoriety: GRCE and IMVT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GRCE: 57% vs. IMVT: 202%
Market capitalization -- GRCE: $41.21M vs. IMVT: $2.75B
GRCE [@Biotechnology] is valued at $41.21M. IMVT’s [@Biotechnology] market capitalization is $2.75B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GRCE’s FA Score shows that 0 FA rating(s) are green whileIMVT’s FA Score has 0 green FA rating(s).

  • GRCE’s FA Score: 0 green, 5 red.
  • IMVT’s FA Score: 0 green, 5 red.
According to our system of comparison, GRCE is a better buy in the long-term than IMVT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GRCE’s TA Score shows that 4 TA indicator(s) are bullish while IMVT’s TA Score has 7 bullish TA indicator(s).

  • GRCE’s TA Score: 4 bullish, 4 bearish.
  • IMVT’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, IMVT is a better buy in the short-term than GRCE.

Price Growth

GRCE (@Biotechnology) experienced а -0.67% price change this week, while IMVT (@Biotechnology) price change was +1.90% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.22%. For the same industry, the average monthly price growth was +31.37%, and the average quarterly price growth was +12.88%.

Reported Earning Dates

GRCE is expected to report earnings on Jun 23, 2025.

IMVT is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+4.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IMVT($2.75B) has a higher market cap than GRCE($41.2M). GRCE YTD gains are higher at: -20.321 vs. IMVT (-35.002). GRCE has higher annual earnings (EBITDA): -16.72M vs. IMVT (-437.78M). IMVT has more cash in the bank: 714M vs. GRCE (11.1M). GRCE (0) and IMVT (0) have equivalent revenues.
GRCEIMVTGRCE / IMVT
Capitalization41.2M2.75B1%
EBITDA-16.72M-437.78M4%
Gain YTD-20.321-35.00258%
P/E RatioN/AN/A-
Revenue00-
Total Cash11.1M714M2%
Total DebtN/A98K-
FUNDAMENTALS RATINGS
GRCE vs IMVT: Fundamental Ratings
GRCE
IMVT
OUTLOOK RATING
1..100
5659
VALUATION
overvalued / fair valued / undervalued
1..100
53
Fair valued
44
Fair valued
PROFIT vs RISK RATING
1..100
46100
SMR RATING
1..100
9497
PRICE GROWTH RATING
1..100
5264
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a27

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IMVT's Valuation (44) in the null industry is in the same range as GRCE (53) in the Pharmaceuticals Other industry. This means that IMVT’s stock grew similarly to GRCE’s over the last 12 months.

GRCE's Profit vs Risk Rating (46) in the Pharmaceuticals Other industry is somewhat better than the same rating for IMVT (100) in the null industry. This means that GRCE’s stock grew somewhat faster than IMVT’s over the last 12 months.

GRCE's SMR Rating (94) in the Pharmaceuticals Other industry is in the same range as IMVT (97) in the null industry. This means that GRCE’s stock grew similarly to IMVT’s over the last 12 months.

GRCE's Price Growth Rating (52) in the Pharmaceuticals Other industry is in the same range as IMVT (64) in the null industry. This means that GRCE’s stock grew similarly to IMVT’s over the last 12 months.

GRCE's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as IMVT (100) in the null industry. This means that GRCE’s stock grew similarly to IMVT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GRCEIMVT
RSI
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
81%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
77%
Momentum
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
77%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 19 days ago
79%
Bullish Trend 22 days ago
77%
Declines
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 5 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
84%
Aroon
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
GRCE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IMVT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ETADX19.380.08
+0.42%
Eventide Dividend Growth A
AAAPX12.32N/A
N/A
DWS RREEF Real Assets C
VDVIX14.06N/A
N/A
Vanguard Developed Markets Index Inv
HEONX17.05N/A
N/A
Hartford Climate Opportunities C
SGIGX33.42N/A
N/A
Steward Global Equity Income Fund R6

GRCE and

Correlation & Price change

A.I.dvisor indicates that over the last year, GRCE has been loosely correlated with IMVT. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if GRCE jumps, then IMVT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GRCE
1D Price
Change %
GRCE100%
+1.36%
IMVT - GRCE
38%
Loosely correlated
-1.77%
SLNO - GRCE
38%
Loosely correlated
-0.92%
CYTK - GRCE
36%
Loosely correlated
-2.21%
SCNI - GRCE
31%
Poorly correlated
-7.69%
ATAI - GRCE
30%
Poorly correlated
-2.67%
More

IMVT and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMVT has been loosely correlated with ROIV. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if IMVT jumps, then ROIV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMVT
1D Price
Change %
IMVT100%
-1.77%
ROIV - IMVT
61%
Loosely correlated
-1.81%
OCUL - IMVT
51%
Loosely correlated
-2.43%
CGON - IMVT
50%
Loosely correlated
-0.46%
IDYA - IMVT
49%
Loosely correlated
-4.04%
XENE - IMVT
49%
Loosely correlated
+0.65%
More